| Rubicon Water Limited (RWL) ORDINARY FULLY PAID |
Information Technology |
$31 |
1H26 Results Presentation
|
27 Feb 2026 9:35AM |
$0.180 |
$0.130 |
fallen by
27.78%
|
|
RWL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased to A$29.0 million due to stronger Australian dollar and US funding issues
- Underlying EBITDA loss of A$5.9 million
- Significant contract signings in Europe, Latin America, and the US totaling A$11.9 million
- Introduction of FloodGateTM for floodplain management in Australia
- First corporate-funded project secured
- Anticipate improved US market conditions in H2 FY26
- Strong near-term pipeline with major projects expected to contribute to growth
- Policy-backed growth opportunities globally
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$24 |
R&D rebate strengthens cash position
|
27 Feb 2026 9:35AM |
$0.065 |
$0.077 |
risen by
18.46%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- Noxopharm Limited received a $2.8 million R&D rebate.
- The rebate strengthens the company's cash position.
- Funds are under the Australian Government's R&D Tax Incentive scheme.
- Supports Sofra™ technology platform development.
- Focuses on continuing success in HERACLES clinical trial.
- Targets treatment for cutaneous lupus and other chronic diseases.
- The global market for cutaneous lupus is valued at over US$3.3 billion.
- Sofra technology could impact autoimmune and cancer treatment markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 6K Additive, Inc (6KA) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$135 |
Full Year 2025 Results Investor Presentation
|
27 Feb 2026 9:35AM |
$0.875 |
$0.780 |
fallen by
10.86%
|
|
6KA - Price-sensitive ASX Announcement
Full Release
Key Points
- Sustained demand for 6KA’s powder driven by production parts usage.
- Strong customer demand in suppressor market for nickel and titanium powders.
- DLA program demonstrated successful upcycling of government scrap.
- Revenue growth in 2H25 accelerated by 37% HoH.
- Successful commissioning of the atomizer boosted nickel sales.
- Gross margin loss reduced by 80% HoH into 2H25.
- Introduced service revenue model for titanium SWARF processing.
- Secured $1.9M order from a US-based aluminum producer.
- Raised $40M through ASX listing in December 2025.
- Expansion plans include new UniMelt systems and increased capacity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austral Gold Limited (AGD) ORDINARY FULLY PAID |
Materials |
$107 |
Austral Gold Files Appendix 4E Preliminary Final 2025 Report
|
27 Feb 2026 9:35AM |
$0.210 |
$0.160 |
fallen by
23.81%
|
|
AGD - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax for FY25 was US$14.7 million.
- Total FY25 production was 15,392 gold equivalent ounces (GEOs).
- Revenue from ordinary activities increased by 39.1% to US$51.17 million.
- Reopened Casposo Mine in Argentina contributed 4,283 GEOs.
- Production at Guanaco Mine Complex in Chile was 11,109 GEOs.
- Production guidance for 2026 is set at 27,000–33,000 GEOs.
- Average realised price was US$3,576 per GEO.
- Cash and cash equivalents increased to US$10.5 million.
- Financial debt remained at US$26.6 million.
- The company sold shares of Unico Silver for net proceeds of US$4.7 million.
- A private placement raised approximately US$5.9 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Latrobe Magnesium Limited (LMG) ORDINARY FULLY PAID |
Materials |
$56 |
Latrobe Magnesium Achieves Continuous MgO Production
|
27 Feb 2026 9:34AM |
$0.020 |
$0.018 |
fallen by
10%
|
|
LMG - Price-sensitive ASX Announcement
Full Release
Key Points
- Development of a magnesium metal Demonstration Plant in Victoria's Latrobe Valley.
- Utilizing a patented extraction process on industrial ash waste.
- First half of the plant achieved sustained magnesium oxide production.
- Full Demonstration Plant commissioning expected in second half of 2026.
- Planned Commercial Plant with 10,000 tonnes per annum capacity.
- International 'Mega' Plant in Sarawak, Malaysia for 100,000 tonnes annually.
- Commitment to recycling, reducing landfill, and low carbon emissions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 6K Additive, Inc (6KA) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$135 |
Appendix 4G and Corporate Governance Statement
|
27 Feb 2026 9:34AM |
$0.875 |
$0.780 |
fallen by
10.86%
|
|
| Rubicon Water Limited (RWL) ORDINARY FULLY PAID |
Information Technology |
$31 |
1H26 Results Release
|
27 Feb 2026 9:34AM |
$0.180 |
$0.130 |
fallen by
27.78%
|
|
RWL - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY26 revenue of A$29.0m, down A$3.0m
- Underlying EBITDA loss of A$5.9m
- Record European contract signings of A$6.9m
- Strong Latin American contract momentum
- First corporate-funded contract in the US worth A$2.3m
- Potential A$30m in tender projects
- A$9.3m in new work contracted in H2 FY26
- Expecting a stronger second half of FY26
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medallion Metals Limited (MM8) ORDINARY FULLY PAID |
Materials |
$338 |
Acquisition Completion
|
27 Feb 2026 9:34AM |
$0.425 |
$0.425 |
fallen by
0%
|
|
MM8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of the acquisition of Forrestania Nickel Operation from IGO Limited.
- Forrestania Nickel Operation to be renamed Forrestania Gold Project.
- Medallion assumes full statutory and operational responsibility for the asset.
- Acquisition provides control over critical processing infrastructure.
- Transaction supports Medallion's long-term gold processing and development strategies.
- Key approvals, funding, and transaction milestones achieved.
- Handover set for 27 February 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| St George Mining Limited (SGQ) ORDINARY FULLY PAID |
Materials |
$531 |
Trading Halt
|
27 Feb 2026 9:33AM |
$0.160 |
$0.135 |
fallen by
15.63%
|
|
SGQ - Price-sensitive ASX Announcement
Full Release
Key Points
- St George Mining Limited requested a trading halt on its securities.
- Trading halt is pending an announcement regarding a substantial increase to the Company's Mineral Resource Estimate at the Araxa Project.
- The trading halt will remain until the earlier of the announcement release or the commencement of normal trading on Tuesday, 3 March 2026.
- St George Mining is not aware of any reason why the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$161 |
ACW successfully completes $16.8m Placement and SPP
|
27 Feb 2026 9:33AM |
$0.042 |
$0.045 |
risen by
7.14%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical successfully completed a $16.8 million capital raising.
- $4.8 million was raised via a share purchase plan (SPP).
- The capital raising included a $12.0 million placement.
- The SPP was offered at $0.042 per share.
- 114 million new shares will be issued to SPP participants.
- CEO Dr. Steven Gourlay and non-executive directors committed to purchasing additional shares.
- The funds will support the XanaMIA phase 2b/3 Alzheimer’s trial and other initiatives.
- The company expects to have a cash balance of $29.5 million by December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rubicon Water Limited (RWL) ORDINARY FULLY PAID |
Information Technology |
$31 |
1H26 Appendix 4D and Half Year Report
|
27 Feb 2026 9:33AM |
$0.180 |
$0.130 |
fallen by
27.78%
|
|
RWL - Price-sensitive ASX Announcement
Full Release
Key Points
- Rubicon Water Limited reported a net loss after tax of $6,390,000 for the six months ended 31 December 2025.
- Revenue for the first half of 2025 was $29,022,000, down from $32,018,000 in the same period of 2024.
- The most significant revenue decline occurred in the ANZ segment, primarily due to decreased hardware and spare parts sales.
- Underlying EBITDA was a loss of $5,854,000, compared to a loss of $1,694,000 in the previous year.
- Rubicon Water Limited did not declare or pay any dividends during the reporting period.
- Net tangible assets per ordinary security decreased from $0.27 in 2024 to $0.21 in 2025.
- Exchange rate fluctuations contributed to a $2.1 million negative impact year-on-year due to a stronger Australian dollar.
- The Asia segment is expected to recover in the second half of the year with increased project activity.
- The company has joint ventures, including Medha Rubicon Water Technologies Pvt Ltd, in which it holds a 50% ownership interest.
- No significant events occurred after the reporting date that would impact the financial statements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$63 |
Application for quotation of securities - NUZ
|
27 Feb 2026 9:32AM |
$0.100 |
$0.085 |
fallen by
15%
|
|
| HeraMED Limited (HMD) ORDINARY FULLY PAID |
Health Care |
$54 |
Annual Report to shareholders
|
27 Feb 2026 9:32AM |
$0.036 |
$0.047 |
risen by
30.56%
|
|
| Alpha HPA Limited (A4N) ORDINARY FULLY PAID |
Materials |
$984 |
Application for quotation of securities - A4N
|
27 Feb 2026 9:32AM |
$0.650 |
$0.678 |
risen by
4.23%
|
|
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$6 |
Appendix 4D and Half Year Financial Report
|
27 Feb 2026 9:32AM |
$0.081 |
$0.064 |
fallen by
20.99%
|
|
IVX - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss after income tax for the half-year: $3,565,836
- Total assets as of 31 December 2025: $8,088,461
- Net assets as of 31 December 2025: $5,706,180
- No dividends paid or declared during the period
- Convertible notes issued for additional funding
- Significant expenditure on research and development
- PhotosoftTM technology focus and potential Orphan Drug Designation
- R&D tax incentive loan facility secured
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$368 |
FY25 Appendix 4E Preliminary Final Report
|
27 Feb 2026 9:31AM |
$1.235 |
$1.250 |
risen by
1.21%
|
|
KSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Net Profit After Tax increased by 20% to PGK 120.7 million.
- Revenue from ordinary activities rose by 13% to PGK 545.5 million.
- Net interest income increased by 20%.
- Foreign exchange income grew by 17%.
- Unfranked dividends declared at AUD 6.5 cents per share.
- Operating expenses increased by 4%.
- Cost-to-income ratio improved to 54.7%.
- Loans and advances to customers increased by 13%.
- Capital adequacy ratios remained strong at 17.1%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$729 |
2025 Financial Results and Corporate Update
|
27 Feb 2026 9:31AM |
$8.870 |
$7.500 |
fallen by
15.45%
|
|
AVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Initiated global pivotal PARADIGM Trial.
- Favorable 30-day and 1-year outcomes for DurAVR® THV.
- First successful double DurAVR® implant.
- Strengthened operational infrastructure and manufacturing capabilities.
- ISO 13485 certification for DurAVR® THV production.
- Net operating cash outflows of US$77.8 million in 2025.
- R&D expenses totaled US$69.1 million.
- Secured US$320 million in capital raises, including Medtronic investment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Platinum International Fund (Quoted Managed Hedge Fund) (PIXX) |
Financials |
$77 |
2026 Interim Financial Report
|
27 Feb 2026 9:31AM |
$5.050 |
$5.150 |
risen by
1.98%
|
|
| Associate Global Partners Limited (APL) ORDINARY FULLY PAID |
Financials |
$17 |
Investor Presentation February 2026
|
27 Feb 2026 9:30AM |
$0.180 |
$0.300 |
risen by
66.67%
|
|
APL - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive net inflows recorded in H1 FY2026.
- FUM reached $1.42 billion by December 2025.
- WCM product suite contributed significantly to FUM growth.
- Partnership with Switzer Financial Group enhances direct business capabilities.
- Strategic focus on expanding manager partnerships and launching new products.
- Achieved operating profitability in H1 FY26.
- Revenue increased by 10.2% in H1 FY26.
- Net loss reduced by 92.3% in H1 FY26.
- Five consecutive quarters of positive operating cash flow achieved.
- Ongoing initiatives to diversify investor base and drive sustainable growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bass Oil Limited (BAS) ORDINARY FULLY PAID |
Energy |
$22 |
Operations Update - January 2026
|
27 Feb 2026 9:30AM |
$0.050 |
$0.059 |
risen by
18%
|
|
BAS - Price-sensitive ASX Announcement
Full Release
Key Points
- Total sales revenue for January was A$471,374 net to Bass.
- Daily oil production for the group averaged 237 bopd for the month.
- Total Cooper Basin monthly production was 2,746 barrels.
- Total Indonesian oil production was 4,596 barrels net to Bass.
- Vanessa acquisition was approved by the regulator.
- Bass secured $3.5 million grant funding for Kiwi gas field development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Raiz Invest Limited (RZI) ORDINARY FULLY PAID |
Financials |
$62 |
Strong Revenue Growth,Improved Profitability & Positive NPAT
|
27 Feb 2026 9:30AM |
$0.605 |
$0.590 |
fallen by
2.48%
|
|
RZI - Price-sensitive ASX Announcement
Full Release
Key Points
- Raiz Invest Limited reported a strong 23.9% revenue growth for the half-year ended 31 December 2025.
- Funds Under Management (FUM) increased by 28.5% to $2.1 billion.
- Raiz achieved a Net Profit After Tax (NPAT) of $3.52 million, transitioning from a previous loss.
- The company's operating cash flows increased by 51.4% to $2.36 million.
- Underlying EBITDA increased by 270% to $2.6 million.
- Raiz's active customer base grew by 5.7% to 336,048.
- Raiz introduced new product offerings like the low-cost Raiz Lite Plan and expanded its product roadmap for 2026.
- The company maintained strategic partnerships to enhance product offerings and entered new partnerships to promote financial education.
- Raiz's Plus Plan portfolios increased by 33.6%, reflecting strong market acceptance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Platinum Asia Fund (Quoted Managed Hedge Fund) (PAXX) |
Financials |
$306 |
2026 Interim Financial Report
|
27 Feb 2026 9:29AM |
$6.460 |
$6.290 |
fallen by
2.63%
|
|
| GLG Corp Limited (GLE) ORDINARY FULLY PAID |
Consumer Discretionary |
$11 |
Half Year Financial Report and Appendix 4D
|
27 Feb 2026 9:29AM |
$0.115 |
$0.145 |
risen by
26.09%
|
|
GLE - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 18.7% to US$54.1m.
- Gross profit margin improved from 17.7% to 18.9%.
- Net loss after tax was US$0.5m compared to a profit of US$0.4m in the previous period.
- No interim dividend recommended for the period ended 31 December 2025.
- Finance costs increased by 10.1% due to higher working capital requirements.
- Cash and cash equivalents decreased slightly by US$0.2m.
- Trade and other receivables decreased by 9.5%.
- Inventory decreased by 14.8% due to lower customer orders.
- Administrative expenses fell by 8.4% through cost control measures.
- Management focuses on working capital optimization and liquidity preservation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| One Click Group Limited (1CG) ORDINARY FULLY PAID |
Industrials |
$12 |
Appendix 4E and Annual Report to Shareholders
|
27 Feb 2026 9:27AM |
$0.009 |
$0.009 |
fallen by
0%
|
|
1CG - Price-sensitive ASX Announcement
Full Release
Key Points
- Consolidated revenue increased from $4.88 million in 2024 to $6.12 million in 2025.
- The company reported a net loss after tax of $716,460 for 2025 compared to a loss of $1.98 million in 2024.
- Total assets for 2025 stood at $4.67 million, slightly higher than $4.53 million in 2024.
- The company's equity increased to $3.64 million in 2025 from $2.94 million in 2024.
- Significant shareholdings and options details include various family accounts and trusts holding substantial percentages.
- Directors and key management personnel hold significant options and performance rights.
- The company engaged in share-based payments and financial transactions to manage equity and reserves.
- Employee expenses and other operational costs were reported with specific focus on superannuation and other benefits.
- The company did not engage in any on-market buy-back activities during the year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$37 |
Update - Notification of buy-back - MEC
|
27 Feb 2026 9:27AM |
$1.195 |
$1.210 |
risen by
1.26%
|
|
Call 1300 880 160
Start a chat
Schedule a call
